Press Releases

<< Back
Printer Friendly Version View printer-friendly version
BeiGene to Participate in the LEERINK Partners 6th Annual Global Healthcare Conference

CAMBRIDGE, Mass., Feb. 08, 2017 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE), a clinical-stage biopharmaceutical company developing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced that the company will present at the LEERINK Partners 6th Annual Global Healthcare Conference in New York, NY. The presentation is scheduled for 1:00 PM ET on February 16, 2017.

A live webcast can be accessed from the investors section of BeiGene’s website at http://ir.beigene.com/. An archived replay will be available for 90 days following the event.

About BeiGene

BeiGene is a global, clinical-stage, research-based biotechnology company focused on molecularly targeted and immuno-oncology cancer therapeutics. With a team of over 300 scientists, clinicians and staff in mainland China, the United States, Australia and Taiwan, BeiGene is advancing a pipeline consisting of novel oral small molecules and monoclonal antibodies for cancer. BeiGene is working to create combination solutions aimed to have both a meaningful and lasting impact on cancer patients.

Investor/Media Contact

Lucy Li, Ph.D.
+1 781-801-1800
ir@beigene.com
media@beigene.com

Primary Logo

BeiGene, LTD.